Literature DB >> 32312782

Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia.

Erdenegerel Narmandakh1, Oyuntuya Tumenbayar1, Tsetsegtuya Borolzoi1, Baasansuren Erkhembayar1, Tsolmon Boldoo1, Naranzul Dambaa1, Buyankhishig Burneebaatar1, Naranbat Nymadawa2, Satoshi Mitarai3, Sarantuya Jav4, Chen-Yuan Chiang5,6,7.   

Abstract

Globally, mutations in the katG gene account for the majority of isoniazid-resistant strains of Mycobacterium tuberculosis Buyankhishig et al. analyzed a limited number of Mycobacterium tuberculosis strains in Mongolia and found that isoniazid resistance was mainly attributable to inhA mutations (B. Buyankhishig, T. Oyuntuya, B. Tserelmaa, J. Sarantuya, et al., Int J Mycobacteriol 1:40-44, 2012, https://doi.org/10.1016/j.ijmyco.2012.01.007). The GenoType MTBDRplus assay was performed for isolates collected in the First National Tuberculosis Prevalence Survey and the Third Anti-Tuberculosis Drug Resistance Survey to investigate genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis in Mongolia. Of the 409 isoniazid-resistant isolates detected by the GenoType MTBDRplus assay, 127 (31.1%) were resistant to rifampin, 294 (71.9%) had inhA mutations without katG mutations, 113 (27.6%) had katG mutations without inhA mutations, and 2 (0.5%) had mutations in both the inhA and katG genes. Of the 115 strains with any katG mutation, 114 (99.1%) had mutations in codon 315 (S315T). Of the 296 strains with any inhA mutation, 290 (98.0%) had a C15T mutation. The proportions of isoniazid-resistant strains with katG mutations were 25.3% among new cases and 36.2% among retreatment cases (P = 0.03) and 17.0% among rifampin-susceptible strains and 52.8% among rifampin-resistant strains (P < 0.01). Rifampin resistance was significantly associated with the katG mutation (adjusted odds ratio, 5.36; 95% confidence interval [CI], 3.3 to 8.67, P < 0.001). Mutations in inhA predominated in isoniazid-resistant tuberculosis in Mongolia. However, the proportion of katG mutations in isolates from previously treated cases was higher than in those from new cases, and the proportion in cases with rifampin resistance was higher than in cases without rifampin resistance.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium tuberculosis; drug resistance; inhA; katG; mutation

Mesh:

Substances:

Year:  2020        PMID: 32312782      PMCID: PMC7318053          DOI: 10.1128/AAC.00537-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Tomasz Jagielski; Zofia Bakuła; Katarzyna Roeske; Michał Kamiński; Agnieszka Napiórkowska; Ewa Augustynowicz-Kopeć; Zofia Zwolska; Jacek Bielecki
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

2.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 3.  Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.

Authors:  Catherine Vilchèze; William R Jacobs
Journal:  Microbiol Spectr       Date:  2014-08

4.  inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa?

Authors:  B Müller; E M Streicher; K G P Hoek; M Tait; A Trollip; M E Bosman; G J Coetzee; E M Chabula-Nxiweni; E Hoosain; N C Gey van Pittius; T C Victor; P D van Helden; R M Warren
Journal:  Int J Tuberc Lung Dis       Date:  2011-03       Impact factor: 2.373

Review 5.  Isoniazid-resistant tuberculosis: a cause for concern?

Authors:  H R Stagg; M C Lipman; T D McHugh; H E Jenkins
Journal:  Int J Tuberc Lung Dis       Date:  2017-02-01       Impact factor: 2.373

6.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

Authors:  A Banerjee; E Dubnau; A Quemard; V Balasubramanian; K S Um; T Wilson; D Collins; G de Lisle; W R Jacobs
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

7.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

Review 8.  Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis.

Authors:  S Borrell; S Gagneux
Journal:  Int J Tuberc Lung Dis       Date:  2009-12       Impact factor: 2.373

9.  Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic.

Authors:  Jainagul Isakova; Nurmira Sovkhozova; Denis Vinnikov; Zoy Goncharova; Elnura Talaibekova; Nazira Aldasheva; Almaz Aldashev
Journal:  BMC Microbiol       Date:  2018-03-22       Impact factor: 3.605

10.  Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates.

Authors:  Muthuraj Muthaiah; Smita Sunil Shivekar; Vidya Raj Cuppusamy Kapalamurthy; Chitra Alagappan; Anbazhagi Sakkaravarthy; Usharani Brammachary
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-06-20
View more
  1 in total

Review 1.  Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis.

Authors:  Tafere Mulaw Belete
Journal:  Microbiol Insights       Date:  2022-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.